Dianthus Therapeutics (DNTH) Other financing activities (2018 - 2025)

Dianthus Therapeutics' Other financing activities history runs 8 years deep, the most recent figure standing at -$598000.0 for Q3 2025.

• On a quarterly basis, Other financing activities fell 302.03% year-over-year to -$598000.0 in Q3 2025; TTM through Sep 2025 was $477000.0, a 22.31% decrease from a year earlier, with the FY2024 full-year figure at $1.1 million, up 21700.0% from the prior year.
• Other financing activities retreated to -$598000.0 in Q3 2025 per DNTH's latest filing, from $568000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $86.3 million in Q3 2021 and bottomed at -$598000.0 in Q3 2025.
• The 5-year median for Other financing activities is $159000.0 (2024), against an average of $7.3 million.
• Across the five-year window, Other financing activities soared 110558.97% in 2021 and sank 302.03% in 2025, its largest moves.
• Year by year, Other financing activities stood at $86.3 million in 2021, then plunged by 100.06% to -$49000.0 in 2022, then soared by 110.2% to $5000.0 in 2023, then soared by 9420.0% to $476000.0 in 2024, then sank by 225.63% to -$598000.0 in 2025.
• Per Business Quant, the three latest DNTH Other financing activities figures stand at -$598000.0 (Q3 2025), $568000.0 (Q2 2025), and $31000.0 (Q1 2025).